These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1164538)

  • 21. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
    Okada K; Oguchi N; Shinohara K; Tamura N; Ishii K; Noguchi Y; Hayashi S; Yamamoto H; Takeichi M; Fujimoto H; Shirota T; Hayashi T
    Rinsho Ketsueki; 1997 Dec; 38(12):1254-62. PubMed ID: 9455144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
    Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
    Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semiparametric analysis of survival data with left truncation and dependent right censoring.
    Jiang H; Fine JP; Chappell R
    Biometrics; 2005 Jun; 61(2):567-75. PubMed ID: 16011706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
    Crocetti E; Mangone L; Lo Scocco G; Carli P
    Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive risk group refinement.
    LeBlanc M; Moon J; Crowley J
    Biometrics; 2005 Jun; 61(2):370-8. PubMed ID: 16011683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The global impact of noncommunicable diseases: estimates and projections.
    Manton KG
    World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.
    Tricot G; Jagannath S; Vesole DH; Crowley J; Barlogie B
    Bone Marrow Transplant; 1995 Jul; 16(1):7-11. PubMed ID: 7581132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival.
    Abbott KC; Agodoa LY
    Clin Nephrol; 2001 Sep; 56(3):207-10. PubMed ID: 11597035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individual therapy-dependent prognosis based on data from controlled clinical trials in chronic liver disease.
    Christensen E
    Dan Med Bull; 1988 Apr; 35(2):167-82. PubMed ID: 3282812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extreme regression.
    LeBlanc M; Moon J; Kooperberg C
    Biostatistics; 2006 Jan; 7(1):71-84. PubMed ID: 15972888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of accessing medical records by date of death on estimates of survival.
    Tallis GM; Leppard P; Sarfaty G
    Biometrics; 1978 Dec; 34(4):662-4. PubMed ID: 749949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
    Durie BG; Jacobson J; Barlogie B; Crowley J
    J Clin Oncol; 2004 May; 22(10):1857-63. PubMed ID: 15111617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hazard function and life table: an introduction to the failure time analysis.
    Matsushita K; Inaba H
    Jinko Mondai Kenkyu; 1987 Apr; (182):36-50. PubMed ID: 12314929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer-assisted predictive formulas expressing survival probability and life expectancy in US adults, men and women, 2001.
    Chung SJ
    Comput Methods Programs Biomed; 2007 Jun; 86(3):197-209. PubMed ID: 17459517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [High life expectancy in multiple myeloma].
    Antipova LG; Andreeva NE
    Ter Arkh; 1985; 57(7):11-4. PubMed ID: 4049260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The analysis of rates using Poisson regression models.
    Frome EL
    Biometrics; 1983 Sep; 39(3):665-74. PubMed ID: 6652201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.